본문 바로가기
KERD
논문KCI 등재

폐경 후 골다공증의 최신 치료

Current Treatment of Postmenopausal Osteoporosis

김정구|윤상호
대한산부인과학회 (Korean Soceity of Obstetrics and Gynecology)|2005.04|Obstetrics & Gynecology Science|제48권 제4호|pp. 844-856

2

조회

0

다운로드

15

인용

0

참고문헌

주제분류산부인과학

초록

Abstract

Osteoporosis is a silent disease which causes a serious morbidity such as fracture. Once osteoporosis risk has been established in postmenopausal women, dietary and lifestyle changes, such as exercise, discontinuing tobacco and alcohol use, are helpful in the prevention of osteoporosis. Fall prevention, calcium and vitamin D supplementation remain the foundation. When pharmacologic intervention is warranted, bisphosphonates and selective estrogen receptor modulator have shown the benefit in preventing bone loss and lowering fracture rates. Short term use of estrogen can be considered for the prevention and treatment of osteoporosis in the postmenopausal women with vasomotor symptoms. Calcitonin and parathyroid hormone are also options for the treatment of osteoporosis. Several new agents are in late-stage development and may offer another treatment alternatives.

참고문헌 (39)

  1. "Standing committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine Dietary reference intakes from calcium" (1997), National Academy Press
  2. "Relation between vitamin D insufficiency and bone metabolism in healthy postmenopausal women", 16, pp.1408~1415 (2001)
  3. "한국 폐경여성에서 비타민 D 부족증에 관한 연구", 1, pp.12~21 (2003)
  4. "Effects of hormone replacement therapy on clinical fractures and height loss", 110, pp.442~450 (2001)
  5. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial", 288, pp.321~333 (2002)
  6. "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy", 291, pp.1701~1712 (2004)
  7. "Recommendations for estrogen and progestogen use in peri- and postmenopausal women", 11, pp.589~600 (2004)
  8. "statements on postmenopausal hormone therapy", 48, pp.19~25 (2004)
  9. "Guidelines for hormonal treatment of women in the menopausal transition and beyond", 7, pp.333~337 (2004)
  10. "Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women", 86, pp.1890~1897 (2001)
  11. "Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass", 5, pp.143~149 (2002)
  12. "Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fracture", 348, pp.1535~1541 (1996)
  13. "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures:results from the Fracture Intervention Trial", 280, pp.2077~2082 (1998)
  14. "Fracture risk reduction with alendronate in women with osteoporosis", 85, pp.4118~4124 (2000)
  15. "Ten years' experience with alendronate for osteoporosis in postmenopausal women", 350, pp.1189~1199 (2004)
  16. "Effects of risedronate treatment on vertebral and non- vertebral fractures in women with postmenopausal osteoporosis Vertebral Efficacy with Risedronate Therapy", 282, pp.1344~1352 (1999)
  17. "Seven years of treatment with risedronate in women with postmenopausal osteoporosis", 75, pp.462~468 (2004)
  18. "Intravenous zoledronic acid in postmenopausal women with low bone mineral density", 346, pp.653~ (2002)
  19. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation", 282, pp.637~645 (1999)
  20. "Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial", 33, pp.293~300 (2003)
  21. "Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years", 10, pp.337~344 (2003)
  22. "The effect of raloxifene on markers of bone turnover in older women living in long- term care facilities", 52, pp.779~783 (2004)
  23. "Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis", 87, pp.985~992 (2002)
  24. "Ten years of treatment with tibolone 2 effects on bone loss in postmenopausal women", 5, pp.390~398 (2002)
  25. "Carcinoma of the endometrium in patients treated with tibolone", 93, pp.568~570 (2004)
  26. "In vitro studies of tibolone in breast cells", 78, pp.351~359 (2002)
  27. "The effect of tibolone and estrogen-based HT on breast cell proliferation and mammographic density", 49, pp.16~21 (2004)
  28. "Beast cancer and hormone-replacement therapy in the Million Women Study", 362, pp.419~427 (2003)
  29. "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the Preventive Recurrence of Osteoporotic Fracture", 109, pp.267~276 (2000)
  30. "Calcitonin for preventing and treating corticosteroid induced osteoporosis The Cochrane Database of Systematic Reviews 2000" (2000)
  31. "Analgesic effects of calcitonin", 30(5), pp.71~74 (2002)
  32. "Fluoride for treating postmenopausal osteoporosis The Cochrane Database of Systemactic Reviews 2000"
  33. "Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis", 344, pp.1434~1441 (2001)
  34. "Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women", 17, pp.1151~1161 (2002)
  35. "The effect of parathyroid hormone or both in men with osteoporosis", 349, pp.1216~1226 (2003)
  36. "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis", 350, pp.459~468 (2004)
  37. "A phase I study of AMAN-0007 in patients with multiple myeloma or breast carcinoma related bone metastasis", 97, pp.887~892 (2003), a recombinant osteoprotegerin construct
  38. "A single- dose placebo controlled study of AMG 162 a fully human monoclonal antibody to RANKL", 19, pp.1059~1066 (2004)
  39. "Disabling of RANK receptor complex by novel osteoprotegerin like peptidomimetics restores bone loss in-vivo", 27, pp.8269~8277 (2004)

관련 논문AI추천

골다공증의 치료정윤석대한내과학회 · 대한내과학회지2010 · 제79권 제3호골다공증의 치료최희정대한가정의학회 · Korean Journal of Family Medicine2004 · 제25권 제2호골다공증에서 알렌드로네이트 투여 시 에스트로젠 용량에 따른 치료 효과김기찬, 이상진, 정호중, 하호성대한재활의학회 · Annals of Rehabilitation Medicine2006 · 제30권 제3호골다공증성 고관절 골절의 약물 치료민병우대한고관절학회 · Hip and Pelvis2006 · 제18권 제4호폐경 후 골다공증 환자에서 여성호르몬과 알렌드로네이트(Alendronate) 병합치료가 단기간의 골대사에 미치는 효과강무일, 김상우, 노성일, 백기현, 오기원, 오은숙, 윤은주, 이덕철, 이원영대한내과학회 · 대한내과학회지2002 · 제63권 제3호폐경 후 골다공증에서 랄록시펜과 저용량 불소의 2년간 병합요법의 효과김기찬, 정석모대한재활의학회 · Annals of Rehabilitation Medicine2007 · 제31권 제2호

이 간행물의 다른 논문 (13건)

성폭행 환자의 처치지침이임순pp. 821-843임신성당뇨의 예측인자로써의Unconjugated Estriol의 유용성강재성, 이규완, 오민정, 김선행, 나중열, 장재혁, 정유아, 한지운pp. 867-874태아 성장 발육장애 또는 전자간증 태반에서의 세포고사:Bcl-2, Bax 및 p53 단백 발현에 관한 연구송은섭, 이우영, 박지현, 임문환, 이병익, 김세련pp. 891-900산후 4주의 우울 증상에 대한 심리사회적 및 산과적예측변인에 대한 연구김재원, 김헌, 김정화, 은대숙pp. 901-909부인암에서 혈중 prealbumin의 임상적 의미김복자, 김영태, 김재욱, 김성훈, 노종환, 남미숙pp. 929-937
원문 보기